It is an honor and we are grateful to London Drugs to be recognized as the “London Drugs 2020 Outstanding Partner of the Year Award”. At Sandoz Canada, going above and beyond to deliver timely and innovative solutions that ensure accessibility of healthcare to Canadian patients is part of our daily vow. We are proud to partner with retailers such as London Drugs, and we recognize the role of pharmacies – as versatile as it is crucial – as one of the cornerstones of access to healthcare that Canadians need.
As of September 30, 2020, PrZiextenzo® (pegfilgrastim) and PrRiximyo®(rituximab for injection) are now eligible for reimbursement in Quebec through the RAMQ’s Public Prescription Drug Insurance Plan.
In addition, both biosimilars are on the list of medicines and establishments for use in Canadian hospitals.
As of October 7, 2020, PrRiximyo® is also eligible for reimbursement in Nova Scotia through the Nova Scotia Pharmacare.
For more information on Sandoz biosimilars click here and to get evidence-based information on biosimilars in Canada visit The Biosimilars Generation web site.
Novartis and Sandoz are responding to the coronavirus situation with safety of associates and patients our primary concern. We are also supporting communities, contributing to research efforts and keeping generic medicine prices stable.
Under the BC Biosimilars Initiative whose implementation started in May 2019, British Columbia PharmaCare announced on August 21, 2020 that it is changing coverage of rituximab medicines for PharmaCare covered patients, including patients on rituximab for rheumatoid arthritis. In consultation with their healthcare professional, patients currently covered for the original-brand rituximab will switch to a rituximab biosimilar such as Riximyo® within six months for continued coverage.
Click here for more details on BC Biosimilars switch policy for rituximab and to read B.C. Ministry of Health’s news release.
This site is intended for an audience in Canada